While the P2ry14 inhibitor (PPTN) has poor PK properties (Robichaud et al., 2011), when drug candidates targeting P2ry14 become available, they may be useful for prevention or treatment of NF1-driven neurofibromas. The gene discussed is NF1; the disease is plexiform neurofibroma.